Seen, Dong Seung, Ph.D
Chief Executive Officer
Dr. Seen is the founder and CEO of GPCR Therapeutics, Inc. since 2013 and before then, he served as a managing director at Macrogen. Previously, Dr. Seen worked at Neurogenex(later Newgex) from 2001 to 2012 and led M&A with Boram Pharm. Co., Inc. as a CEO. Earlier in his career, he worked as a biotech researcher at LG Chemical.
Dr. Seen earned his BS, MS and Ph.D from Seoul National University.
Huh, Won-Ki, Ph.D
Dr. Huh is the co-founder of GPCR Therapeutics, Inc. He is a professor at the Department of Biological Sciences, Seoul National University, running the laboratory of Molecular and Cellular Proteomics.
Dr. Huh obtained his BS, MS and Ph.D from Seoul National University.
Pina Cardarelli, Ph.D
Chief Scientific Officer
Dr. Cardarelli is the vice president of R&D and is the CSO of GPCR Therapeutics, Inc. She served as a vice president of Cell Biology and Pharmacology at Bristol-Myers Squibb (BMS) where she was leading multiple targeted oncology programs and was a critical contributor to immuno-oncology projects. Previously, Dr. Cardarelli worked at Medarex (later acquired by BMS) as a vice president. Earlier in her career, she worked at Corixa, Coulter, and Tanabe.
Dr. Cardarelli earned her Ph.D from Albany Medical College.
Lee, Tae Gyu, Ph.D
His previous roles include Center Director at Osong New Drug Development Center, Adjunct professor at Chungbuk University, CSO at CrystalGenomics, and Principal Research Scientist at LG Life Sciences.
Dr. Lee earned his BS and MS from Seoul National University, and obtained his Ph.D degree from University of Washington.
Heo, Seong Ryong
Chief Financial Officer
Mr. Heo served as a CFO at Newgex(formerly Neurogenex). Prior to Newgex, he worked at Tongyang Securities and Meritz Securities.
Mr. Heo received his BS from Inha University.
Chief Business Officer
Mr. Imm worked as a director at Reyon Pharmaceutical and Binex. Previously, he had led business development at ViroMed(now Helixmith).
Mr. Imm received his BS and MS from Seoul National University and another MS from University of Edinburgh.
Chief IP Counsel
Ms. Kim received her BS from Seoul National University and admitted to the Korean patent bar in 2001.
Corporate Development Officer
Mr. Shin is the corporate development officer at GPCR Therapeutics, Inc. He served as a Chief Investment Officer at KB Investment. Previously, Mr.Shin worked at KDB Capital and Macrogen.
Mr.Shin earned his BS and MS from Seoul National University, and received an MBA at Korea University.